Diligence memo · auto-generated · as of July 2, 2026
Ziopharm Oncology Inc
Ziopharm Oncology Inc looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Ziopharm Oncology Inc operates in Biotechnology, based in BOSTON.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ziopharm Oncology Inc has raised $369M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $120M on 2016-06-30.
Most recent recorded round closed around 2019-09-12.
Valuation (modeled)modeled
Provath models Ziopharm Oncology Inc at approximately $805M (range $88M–$1.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.19× the median modeled value of Series D+ Biotechnology companies in 2019–2021 (58 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 20 months.
Last raise 6.8 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 5.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 99% of Biotechnology peers (4293 compared).
Modeled value ranks above 87% of those peers.
Closest niche peers: Sarepta Therapeutics, Inc., Asklepios BioPharmaceutical, Inc., Affinivax, Inc., Sonoma Biotherapeutics, Inc., Instil Bio, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.